Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 393 participants.

Also called NCT01647542

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 393 participants (enrolled count) (from the registry)
Sponsor
  • Takeda Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01647542
  • WHO UTN U1111-1129-7865
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Australia, China, New Zealand, South Korea, Taiwan (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01647542. Randomized; quadruple masking; primary purpose treatment. Start 2012-10 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2015-08-19.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes
Acronym
GRAND-307
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
TAK-875
Intervention (Drug)
TAK-875 Placebo
Lead sponsor
Takeda (class: industry)

Record details

Record id
cardio:ct-nct01647542
Content hash
9409571a3004a7c22b1de8c37efdda66004577dbd9683c43f494ab262f30570f